| Epidemiology from Literature | | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | | 1.1 - Asymptomatic | 2014 | Belgium | IgE | 15 | 0.070 | 20140718, Faber MA
| | 1.12 - Oral Allergy Syndrome | 2014 | Belgium | IgE | 38 | 10.530 | 20140718, Faber MA
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Belgium | IgE | 14 | 28.570 | 20140718, Faber MA
| | 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Netherlands | IgE | 211 | 5.700 | 20140331, Rockmann H
| | 1.6 - Anaphylaxis, Diagnosed | 2014 | Belgium | IgE | 37 | 70.270 | 20140718, Faber MA
| | 10.1 - Normal Control | 2014 | Belgium | IgE | 15 | 0.000 | 20140718, Faber MA
| | 3.2.1 - Source Sensitized (IgE) | 2014 | United States | IgE | 29 | 55.200 | 20140606, Kattan JD
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2014 | United States | IgE | 13 | 92.300 | 20140606, Kattan JD
| | 1.3 - Rhinitis, Diagnosed | 2013 | Brazil | IgE | 101 | 0.000 | 20130912, Lacerda Araujo LM
| | 4.1.1 - Heterologous Source Sensitized (Symptoms) | 2013 | Netherlands | IgE | 82 | 12.190 | 20130415, Masthoff LJ
| | 5.1.1 - Source Exposed (Symptoms) | 2013 | Netherlands | IgE | 79 | 59.490 | 20130415, Masthoff LJ
| | 1.2.1 - Asthma, Diagnosed (Adults) | 2012 | Sweden | IgE | 96 | 0.000 | 20120528, Patelis A
| | 10.1 - Normal Control | 2012 | Belgium | IgE | 27 | 0.000 | 20110223, De Knop KJ
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2012 | Spain | IgE | 55 | 25.500 | 20120726, Pedrosa M
| | 4.1.8 - Heterologous Source Sensitized (SPT, IgE) | 2012 | Spain | IgE | 68 | 2.900 | 20120726, Pedrosa M
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2012 | Belgium | IgE | 99 | 15.150 | 20110223, De Knop KJ
| | 6.2 - General Population (Adults) | 2012 | Sweden | IgE | 371 | 0.000 | 20120528, Patelis A
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2010 | Belgium | IgE | 20 | 15.000 | 20100628, Verweij MM
| | 1.5 - Atopic Dermatitis, Diagnosed | 2009 | Germany | IgE | 20 | 5.000 | 20091005, Ott H
| | 10.1 - Normal Control | 2009 | Belgium | IgE | 26 | 0.000 | 20091121, Ebo DG
| | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2009 | Belgium | IgE | 22 | 4.550 | 20091121, Ebo DG
| | 4.1.5 - Heterologous Source Sensitized (IgE) | 2009 | Belgium | IgE | 20 | 0.000 | 20091121, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Belgium | IgE | 37 | 0.000 | 20090826, Ebo DG
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Denmark | IgE | 21 | 19.000 | 20090406, Skamstrup Hansen K
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Spain | IgE | 20 | 50.000 | 20090406, Skamstrup Hansen K
| | 4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE) | 2009 | Switzerland | IgE | 21 | 14.000 | 20090406, Skamstrup Hansen K
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2009 | Denmark | IgE | 20 | 20.000 | 20090406, Skamstrup Hansen K
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2009 | Spain | IgE | 17 | 47.000 | 20090406, Skamstrup Hansen K
| | 5.7.2 - Source Exposed (Provocation Test - Ingestion) | 2009 | Switzerland | IgE | 20 | 25.000 | 20090406, Skamstrup Hansen K
| | 5.3.1 - Source Exposed (Symptoms, IgE) | 2002 | United States | IgE | 14 | 85.700 | |
|
Loading...
Cor a 9
